Did you know,

QuantiFERON® provides a convenient replacement technology for tuberculosis (TB) infection evaluations? Recommended by the CDC for use in certain situations where the tuberculin skin test (TST) is appropriate.[1]

Advantages of QFT

TST Challenges	QFT Offers Improvements
Requires multiple office visits to inject and read the TST reaction.[2]	**One office visit** for single blood draw
Higher false-positive rate (than QFT) with more follow-up required	**>99% specific, nearly eliminating false positives.**[2,3] **Fewer false positives** mean less follow-up.[4] False-positive results may also confound prescribing immunosuppressive therapy or workplace decisions.[5,6]
Subjective result	**Produces an objective result**
May be affected by previous BCG vaccinations	**Unaffected by previous BCG vaccinations**[1]
May boost subsequent TST test results	**Does not boost subsequent QFT test results** and less affected by prior TST[7]
TST approved for use to aid in the evaluation of TB.	**QFT is an approved alternative for use where TST is appropriate. QFT is also preferred** in individuals who have received BCG vaccination or who may not be in compliance for return visits to have a TST read. Less caution might be warranted when using QFT in children ≥5 years old than in children <5 years old.[1]

LabCorp
Laboratory Corporation of America

QuantiFERON (QFT) may help save time with one office visit needed, with >99% specific results, nearly eliminating false positives. Fewer false positives mean less follow-up.[1]

QuantiFERON®-TB Gold 182873
QuantiFERON®-TB Gold (Client Incubated) . . .183244

Send your patients to a LabCorp patient service center (PSC), and we will perform the specimen preparation; or you may collect and carefully follow the essential collection and incubation requirements shown in the Test Menu at www.LabCorp.com.

For more information, ask your LabCorp representative, or visit www.labcorp.com.

References
1. Centers for Disease Control and Prevention. Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection – United States, 2010. *MMWR* 2010;59(NoRR-55).
2. QuantiFERON®-TB Gold [package insert]. Valencia, Calif: Cellestis Inc. 2011.
3. Deil R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-y release assays for detecting active TB: a metaanalysis. *Chest*. 2010;137:952-968.
4. Andersen P, Munk ME, Pollock J M, Doherty TM. Specific immune-based diagnosis of tuberculosis. *Lancet*. 2000;356:1099-1104.
5. Nienhaus A, Schablon A, Le Bâcle CL, Siano B, Diel R. Evaluation of the interferon-y release assay in healthcare workers. *Int Arch Occup Environ Health*. 2007.
6. Beglinger C, Dudler J, Mottet, et al. Screening for tuberculosis infection before initiation of anti-TNF-α therapy. *Swiss Med Wkly*. 2007;137:621-622.
7. Centers for Disease Control and Prevention: Guidelines for using the QuantiFERON®-TB Gold Test for detecting Mycobacterium tuberculosis Infection, United States. 2005;54(NoRR-15).

LabCorp
Laboratory Corporation of America

www.LabCorp.com

QuantiFERON® and QFT® are trademarks of the QIAGEN Group.
©2013 Laboratory Corporation of America® Holdings All rights reserved. L12151-0913-1